血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂治疗糖尿病肾病的临床疗效分析被引量：16

导出

摘要目的探讨血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂在延缓糖尿病肾病患者肾功能衰竭方面的临床疗效。方法选取笔者所在医院糖尿病肾病患者200例,分别给予血管紧张素转换酶抑制剂、血管紧张素受体拮抗剂治疗以及两者联用,观察三组血压、血肌酐及24h尿蛋白定量,并比较三组疗效。结果 3组血压差异无统计学意义(P>0.05),血肌酐方面,培哚普利组与厄贝沙坦组间差异无统计学意义(P>0.05),联合组与贝那普利组和氯沙坦组差异均有统计学意义(P<0.05),24h尿蛋白定量,培哚普利组与厄贝沙坦组间差异无统计学意义(P>0.05),联合组与另外两组间差异均有统计学意义(P<0.05)。结论血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂在糖尿病肾病患者中能够很好的延缓肾衰竭的进程,保护肾功能,两者联用可以取得更好的疗效。

作者黄宇静伍锦泉陈玉平黄力傅壁峰

机构地区广东省肇庆市第一人民医院内三区

出处《中国医药科学》 2012年第3期55-56,共2页 China Medicine And Pharmacy

关键词血管紧张素转换酶抑制剂血管紧张素受体拮抗剂糖尿病肾病

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献4

1孙世澜,曾红兵.老年人糖尿病肾病的治疗[J].中华老年医学杂志,2006,25(1):18-19. 被引量：25
2Thorp ML.Diabetic nephropathy:common questions[J].Am fam physician,2005,72 (1):96299.
3乐伟波,刘志红.肾素-血管紧张素系统与糖尿病肾病[J].肾脏病与透析肾移植杂志,2008,17(4):369-373. 被引量：12
4Brenner BM,Cooper ME,de Zeeuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,2001,345(12):861-869.

二级参考文献34

1Beldent V, Michaud A, Wei L, et al. Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site. J Biol Chem, 1993,268(35 ) :26428 -26434.
2Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int, 1981,19 (3) :410 -415.
3Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest, 1986,77(6) :1925 -1930.
4Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med, 1993,329(20) :1456 -1462.
5Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001,345 (12) :861 - 869.
6Lewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001,345 (12) : 851 - 860.
7Parving HH, Lehnen H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med,2001,345(12) :870 -878.
8Danser AH, Derkx FH, Schalekamp MA, et al. Determinants of interindividual variation of renin and prorenin concentrations: Evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens, 1998,16 ( 6 ) : 853 - 862.
9Daneman D, Crompton CH, Balfe JW, et al. Plasma prorenin as an early marker of nephropathy in diabetic (iddm) adolescents. Kidney Int, 1994,46(4) :1154 - 1159.
10Veniant M, Menard J, Bruneval P, et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest, 1996,98(9):1966- 1970.